全文获取类型
收费全文 | 1912篇 |
免费 | 107篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 12篇 |
儿科学 | 36篇 |
妇产科学 | 19篇 |
基础医学 | 293篇 |
口腔科学 | 101篇 |
临床医学 | 122篇 |
内科学 | 495篇 |
皮肤病学 | 35篇 |
神经病学 | 80篇 |
特种医学 | 47篇 |
外科学 | 387篇 |
综合类 | 3篇 |
一般理论 | 1篇 |
预防医学 | 72篇 |
眼科学 | 7篇 |
药学 | 119篇 |
中国医学 | 2篇 |
肿瘤学 | 210篇 |
出版年
2022年 | 21篇 |
2021年 | 40篇 |
2020年 | 35篇 |
2019年 | 25篇 |
2018年 | 32篇 |
2017年 | 22篇 |
2016年 | 27篇 |
2015年 | 24篇 |
2014年 | 34篇 |
2013年 | 61篇 |
2012年 | 65篇 |
2011年 | 57篇 |
2010年 | 50篇 |
2009年 | 48篇 |
2008年 | 73篇 |
2007年 | 85篇 |
2006年 | 78篇 |
2005年 | 88篇 |
2004年 | 70篇 |
2003年 | 101篇 |
2002年 | 90篇 |
2001年 | 66篇 |
2000年 | 92篇 |
1999年 | 81篇 |
1998年 | 48篇 |
1997年 | 24篇 |
1996年 | 29篇 |
1995年 | 23篇 |
1994年 | 19篇 |
1993年 | 23篇 |
1992年 | 60篇 |
1991年 | 43篇 |
1990年 | 54篇 |
1989年 | 42篇 |
1988年 | 44篇 |
1987年 | 33篇 |
1986年 | 25篇 |
1985年 | 21篇 |
1984年 | 10篇 |
1983年 | 15篇 |
1982年 | 12篇 |
1980年 | 8篇 |
1978年 | 16篇 |
1977年 | 7篇 |
1974年 | 20篇 |
1973年 | 13篇 |
1970年 | 9篇 |
1969年 | 7篇 |
1968年 | 10篇 |
1966年 | 12篇 |
排序方式: 共有2041条查询结果,搜索用时 46 毫秒
101.
Kishimoto S Noguchi T Yamaoka T Fukushima S Takeuchi Y 《Biological & pharmaceutical bulletin》2000,23(5):637-640
SM-11355, cis[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)] platinum(II) is a lipophilic platinum complex. SM-11355 suspended in Lipiodol (SM-11355/Lipiodol) was previously shown to have antitumor effects against rat hepatic tumors after intra-arterial administration. In the present study, the in vitro release of platinum compounds from SM-11355/Lipiodol was examined. A test tube containing 10 ml of saline and 1 ml of SM-11355/Lipiodol was rotated at 5 rpm in a vertical orientation. The platinum concentration in saline gradually increased for 28 d. From HPLC analysis, cyclohexane-1,2-diamineplatinum(II) dichloride (DPC) and cyclohexane-1,2-diamineplatinum(II) chloroiodide (DPCI) were detected in the saline, and the sum of these two compounds was equivalent to the total platinum amount in the saline determined by atomic absorption spectrophotometry at days 21 and 28. DPC showed significant growth inhibitory activities, with IC50 values of 0.1-0.7 nmol/ml in rat hepatoma AH-109A cells and 5 human tumor cell lines, as effective as cisplatin. These findings suggest that SM-11355/Lipiodol exerts antitumor effects by releasing active platinum compounds, and that DPC is one of the candidates of the active compounds. 相似文献
102.
Yoshimura C Nomura S Yamaoka M Ohtani T Matsuzakiz T Yamaguchi K Fukuharal S 《Cancer letters》2000,152(1):87-95
We investigated the relationship between ErbB-2 and HLA in order to clarify the clinical and genetic factors related to Japanese patients with lung cancer. Thirty-nine of the 73 lung cancer patients (53.4%) had elevated levels of ErbB-2. Only seven of 23 (30. 4%) patients with small cell carcinoma had elevated ErbB-2 levels. The prevalence of ErbB-2 positivity was highest (23 of 32; 71.8%) in patients with adenocarcinoma, while that in patients with squamous cell carcinoma was 50% (9 of 18). The frequencies of HLA A33, B44, B62, and B75 were lower in the lung cancer patients than in the control group. HLA-DR9 was higher in frequency in lung cancer patients than in the healthy controls (P<0.05), but HLA-DR6 was lower in frequency in lung cancer patients than in controls (P<0.01). DRB1*0901 was significantly higher in frequency in lung cancer patients than in controls (P<0.05). On the other hand, DRB1*0802, DRB1*1302 and the DRB1*14 group (*1401, *1403, *1405, *1406, and *1407) were completely absent in lung cancer patients. The frequencies of HLA B35, B52, B62, DRB1*0404, and DRB1*0406 were higher in the ErbB-2-positive lung cancer patients than in the ErbB-2-negative lung cancer patients. However, these types of HLA were not included in significant frequencies in our group of lung cancers. Our results suggest that some HLA-antigens/alleles participate in the pathogenesis of lung cancer in Japanese patients. In addition, the relationship between HLA-associated genetic factors and ErbB-2 seems to be weak. These findings suggest that ErbB-2 is correlated with prognostic factors for lung cancer independently of HLA-associated genetic factors. 相似文献
103.
Yasuyuki Nakamura Shinji Tamaki Yasukazu Uchida Nobuyuki Ohmichi Osamu Yamaoka Nobuo Miyauchi Takehisa Fukuhara Harumi Sayama Tetsuhiro Yamada Shinro Matsuo Yutaka Yamada 《Hypertension research》2004,27(3):137-140
To examine whether the response to the angiotensin II receptor antagonist losartan varies depending on the angiotensin converting enzyme (ACE) genotype, we prospectively studied the effect of losartan in 42 hypertensive patients (20 men, 22 women; mean age: 60.4 years). After a 4-week observation period, losartan was administered at 50 mg/day and blood pressure was measured every 2 to 4 weeks for 12 weeks. Among the 42 patients, 19, 11, and 12, respectively, had the II, ID, and DD ACE genotypes. The baseline plasma ACE activity in patients with the ID or DD genotype was significantly higher than that in patients with the II genotype (13.8 +/- 4.2 vs. 9.6 +/- 2.3 IU/l; p = 0.0002). However, age, gender, baseline systolic and diastolic blood pressure (SBP/DBP), and body mass index (BMI) were not different among the groups. After 12 weeks of treatment with losartan alone, DBP in the ID+DD group was significantly higher than that in the II group (85.0 +/- 9.0 vs. 77.8 +/- 9.6 mmHg, p = 0.018), while the percent reduction in DBP in the ID+DD group was significantly smaller than that in the II group (7.9 +/- 8.8 vs. 14.3 +/- 10.1%, p = 0.035). Multiple regression analysis showed that the significant predictors of the DBP at 12 weeks were age (p = 0.030), ACE genotype (p = 0.029) and baseline DBP (p = 0.0001). The ACE genotype may be a determinant of the response to losartan in hypertensive patients. 相似文献
104.
105.
Yamaoka K Fukuda M Hatakeyama S Murayama D Kashiwagi R Musashi T Ohnuki T Miyoshi K Nagai H Nanjo H Miyamoto Y 《Gan to kagaku ryoho. Cancer & chemotherapy》2005,32(10):1411-1414
The purpose of this study was to evaluate the effectiveness and safety of combination chemotherapy with docetaxel (TXT) and nedaplatin (CDGP) for patients with oral squamous cell carcinomas. Eight patients were enrolled in this study (4 men and 4 women, with a mean age of 61.7 years). TXT and CDGP were administered at a dose of 60 mg/m(2) and 70 mg/m(2) by drip infusion for 120 minutes, respectively. Three patients received one more administration 4 weeks after the first one. The locoregional response was evaluated 4 weeks after the final administration of TXT and CDGP. As a result, the locoregional response rate after 1 course was 62.5% including 25.0% of complete response (CR). The response rate after 2 courses was 100.0% with 66.7% of CR. According to Oboshi and Shimosato's classification, histological evaluation of surgical specimens revealed that four cases were Grade IIa, two cases Grade IIb, and two cases Grade IV. The severe adverse events were neutropenia and leukopenia, which were effectively managed with granulocyte colony-stimulating factor (G-CSF). No other severe side effects were recognized. The present study suggested that the combination chemotherapy with TXT and CDGP would be an effective and safe regimen in neo-adjuvant chemotherapy for oral squamous cell carcinomas. 相似文献
106.
Takushima A Harii K Asato H Momosawa A Okazaki M Nakatsuka T 《International journal of clinical oncology / Japan Society of Clinical Oncology》2005,10(4):234-242
Microvascular free flap transfer currently represents one of the most popular methods for mandibularreconstruction. With the various free flap options nowavailable, there is a general consensus that no single kindof osseous or osteocutaneous flap can resolve the entire spectrum of mandibular defects. A suitable flap, therefore, should be selected according to the specific type of bone and soft tissue defect. We have developed an algorithm for mandibular reconstruction, in which the bony defect is termed as either “lateral” or “anterior” and the soft-tissue defect is classified as “none,” “skin or mucosal,” or “through-and-through.” For proper flap selection, the bony defect condition should be considered first, followed by the soft-tissue defect condition. When the bony defect is “lateral” and the soft tissue is not defective, the ilium is the best choice. When the bony defect is “lateral” and a small “skin or mucosal” soft-tissue defect is present, the fibula represents the optimal choice. When the bony defect is “lateral” and an extensive “skin or mucosal” or “through-and-through” soft-tissue defect exists, the scapula should be selected. When the bony defect is “anterior,” the fibula should always be selected. However, when an “anterior” bone defect also displays an “extensive” or “through-and-through” soft-tissue defect, the fibula should be usedwith other soft-tissue flaps. Flaps such as a forearm flap, anterior thigh flap, or rectus abdominis musculocutaneous flap are suitable, depending on the size of the soft-tissue defect. 相似文献
107.
108.
Jiang J Gajalakshmi V Wang J Kuriki K Suzuki S Nakamura S Akasaka S Ishikawa H Tokudome S 《Cancer science》2005,96(8):507-512
The aim of the present study was to investigate associations between Pro12Ala and C161T polymorphisms in the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) gene and colorectal cancer (CRC) risk. We recruited 301 newly diagnosed CRC patients and 291 healthy control subjects at the Madras Cancer Institute in Chennai, India, from 1999 to 2001. Genotypes of the Pro12Ala and C161T polymorphisms were determined using the PCR-RFLP method. After adjustment for age, sex, smoking habit, family history and family income, an increased risk of CRC was observed for the C/T + T/T genotype compared to the C/C genotype of the C161T polymorphism (odds ratio = 1.61, 95% confidence interval: 1.10-2.36), whereas no significant association was found for Pro12Ala (odds ratio = 1.06, 95% confidence interval: 0.70-1.61). Analysis with estimated haplotypes showed a significant difference in haplotype frequencies between cases and controls (chi(2) = 11.62, P = 0.009, d.f. = 3). The relationship between the two polymorphisms and CRC risk was not significantly modified by dietary intake of fish. Although the biological mechanisms of the observed association remain to be elucidated, our findings suggest that the C161T polymorphism of the PPAR-gamma gene is related to risk of CRC. Further research is needed to investigate functional implications of polymorphisms of the PPAR-gamma gene in CRC development. 相似文献
109.
Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma 总被引:9,自引:0,他引:9
Pawlik TM Poon RT Abdalla EK Zorzi D Ikai I Curley SA Nagorney DM Belghiti J Ng IO Yamaoka Y Lauwers GY Vauthey JN;International Cooperative Study Group on Hepatocellular Carcinoma 《Archives of surgery (Chicago, Ill. : 1960)》2005,140(5):450-7; discussion 457-8
HYPOTHESIS: A subset of patients with hepatocellular carcinoma (HCC) with a diameter of 10 cm or larger may benefit from hepatic resection. DESIGN: Retrospective study of a multi-institutional database. SETTING: Five major hepatobiliary centers. PATIENTS: We identified 300 patients who underwent hepatic resection for HCC 10 cm or larger. MAIN OUTCOME MEASURES: Clinical and pathologic data were collected, and prognostic factors were evaluated by univariate and multivariate analyses. Patient survival was stratified according to a clinical scoring system and pathologic T classification. RESULTS: The perioperative mortality rate was 5%. At a median follow-up of 32 months, the median survival was 20.3 months, and the 5-year actuarial survival rate was 27%. Four clinical factors-alpha-fetoprotein of 1000 ng/mL or higher, multiple tumor nodules, the presence of major vascular invasion, and the presence of severe fibrosis-were significant predictors of poor survival (all P<.05). Patients were assigned a clinical score according to the following risk factors: 1, no factor; 2, one or two factors; or 3, three or four factors. On the basis of the clinical score, patients could be stratified into only 2 distinct prognostic groups: no factor (score of 1) vs 1 or more factors (score of 2 or 3) (P<.001). In contrast, when patients were stratified according to pathologic T classification, 3 distinct groups were identified: T1 vs T2 vs T3 and T4 combined (P<.001). Fifty-six percent of the patients with a clinical score of 2 and 20% of patients with a clinical score of 3 actually had T1 or T2 disease on pathologic examination. CONCLUSIONS: Patients with large HCCs should be considered for liver resection as this treatment is associated with a 5-year survival rate exceeding 25%. Clinical predictors should not be used to exclude patients from surgical resection because these factors do not reliably predict outcome. 相似文献
110.
Kandatsu N Nan YS Feng GG Nishiwaki K Hirokawa M Ishikawa K Komatsu T Yokochi T Shimada Y Ishikawa N 《Anesthesiology》2005,102(6):1182-1189
BACKGROUND: The current study was undertaken to investigate the effects of pretreatment with isoflurane and sevoflurane on the development of neurogenic pulmonary edema in an animal model. METHODS: Rats were exposed to room air (control), 1.5% isoflurane, or 2.5% sevoflurane for 4 h. They were then anesthetized with intraperitoneal injections of pentobarbital sodium, and fibrinogen and thrombin were injected into the cisterna magna to induce neurogenic pulmonary edema. RESULTS: Consecutive injections of fibrinogen and thrombin caused increases in blood pressure, with the peak values obtained in the isoflurane and sevoflurane groups being lower than the control values. The incidence of significant neurogenic pulmonary edema was 58%, 100%, and 8% in the control, isoflurane, and sevoflurane groups, respectively. The lung water ratio, an index of severity of edema, was 4.86 +/- 0.78, 6.15 +/- 0.64, and 4.40 +/- 0.32 in the control, isoflurane, and sevoflurane groups, respectively. Furthermore, immunohistochemical staining for vascular endothelial growth factor demonstrated an increase of expression in the rat lungs exposed to isoflurane. Treatment with an anti-vascular endothelial growth factor antibody during exposure to isoflurane completely inhibited the effect of isoflurane to promote neurogenic pulmonary edema in this model. CONCLUSION: Exposure to 1.5% isoflurane enhances the development of neurogenic pulmonary edema development in this animal model, most likely via release of vascular endothelial growth factor from bronchial epithelial cells, an effect not observed with sevoflurane. 相似文献